Quote
—
—
No scored catalysts in the window yet.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
—
Open
—
Prev close
—
Volume
—
Avg volume
—
Dividend
—
IPO
—
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-reports-positive-results-from-drdc-bucillamine-ne-1206464 · 8/12/2026+0.80
https://www.globenewswire.com/news-release/2025/11/21/3192926/0/en/Revive-Therapeutics-Provides-Update-of-Key-Nerve-Agent-Countermeasure-Study.html · 11/21/2025+0.20
https://www.globenewswire.com/news-release/2025/09/19/3153443/0/en/Revive-Therapeutics-Announces-Closing-of-Second-Tranche-of-Private-Placement.html · 9/19/2025+0.20
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
